- CEO
- Sung-Hoon Kwon
- Full Time Employees
- 103
- Sector
- Electronic technology
- Industry
- Electronic components
- Address
- Seoul South Korea
- IPO Date
- Dec 9, 2020
- Business
- QuantaMatrix, Inc. (KRX: 317690) is a South Korea-based in vitro diagnostics company that develops and commercializes advanced clinical microbiology, molecular diagnostics, and immunoassay platforms designed to combat antimicrobial resistance and accelerate critical care diagnostics. Founded in 2010 as a spin-off from Seoul National University and headquartered in Seoul, South Korea, the company operates internationally with regional European operations based in Villejuif, France, and commercial distribution networks spanning Europe, the Middle East, and Asia.
The company categorizes its primary product portfolio across rapid antimicrobial susceptibility testing, infectious disease screening, and automated multi-marker immunoassays: dRAST (direct & Rapid Antimicrobial Susceptibility Testing), an automated clinical platform that provides phenotypic antimicrobial susceptibility test results directly from positive blood culture samples in as little as four to six hours, utilizing microfluidic agarose channels, time-lapse microscopic imaging, and artificial intelligence-driven diagnostic algorithms to guide targeted antibiotic prescription for sepsis; QDST (QuantaMatrix Drug Susceptibility Testing), a rapid phenotypic susceptibility testing system engineered to determine tuberculosis drug resistance in approximately seven days compared to conventional multi-week workflows; QPLEX Alz plus assay, a multi-biomarker in vitro diagnostic kit engineered for early-stage Alzheimer's disease risk assessment via standard blood draws; QMIA (QuantaMatrix Immunoassay Analyzer), an automated multiplex immunoassay instrument utilizing encoded Microdisk technology; and Quanti9 and QuantiGal, prognostic biomarker assay kits utilized for cardiovascular disease research and stratification.
In recent corporate developments, QuantaMatrix has advanced its technological pipeline, regulatory reach, and global commercialization footprint. In September 2025, the company was awarded 2.85 million USD in funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to develop an ultra-rapid diagnostic platform tailored for neonatal sepsis using low-volume blood samples. In 2024, the company unveiled its next-generation uRAST (Ultra-Rapid Antimicrobial Susceptibility Testing) technology in Nature, demonstrating direct phenotypic susceptibility testing from whole blood within 13 hours without preliminary blood culture incubation. To accelerate international market penetration, QuantaMatrix secured European In Vitro Diagnostic Medical Devices Regulation (IVDR) CE certification for its dRAST platform, secured diagnostic tenders including the Great Orchestra of Christmas Charity (WOSP) contract in Poland, established an exclusive distribution partnership with Neo-Science to expand commercial availability across the United Arab Emirates and the Middle East, and advanced pre-submission regulatory discussions under the 510(k) pathway with the U.S. Food and Drug Administration (FDA) to support clinical entry into the North American market.